Loading data for XTLB — first visit, this takes a few seconds.
XTL Biopharmaceuticals Ltd. (XTLB)
NasdaqCM: XTLB
· Real-Time Price · USD
2.49
-0.05 (-1.97%)
At close: Aug 31, 2026, 3:59 PM
The price, the headline numbers and the latest news, in one place.
XTL Biopharmaceuticals Ltd. (XTLB) Stock Price, Analysis & Data
-1.97% (1D)
| Bid | 1.93 |
| Market Cap | 6.12M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -759K |
| 0.46 | |
| -0.36 | |
| n/a | |
| n/a | |
| P/B (ttm) | 0.00 |
| P/S (ttm) | 0.00 |
| Earnings Date | n/a |
| Ask | 3.4 |
| Volume | 7,524 |
| Avg. Volume (20D) | 72,225 |
| Open | 2.57 |
| Previous Close | 2.54 |
| Day's Range | 2.48 - 2.58 |
| 52-Week Range | 2.01 - 10.28 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About XTLB
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commerci...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 1, 2005
Employees 4
Stock Exchange NasdaqCM
Ticker Symbol XTLB
Website https://www.xtlbio.com
Financial Performance
In 2025, XTL Biopharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -6.97M, an increase of 578.58%.
Financial StatementsEarnings Surprise
XTL Biopharmaceuticals has released their quarterly earnings on Jun 1, 2016:
- Revenue of $289K misses estimates by $0, with Infinity% YoY growth.
- EPS of -0.04 misses estimates by , with 33.33% YoY growth.